405 related articles for article (PubMed ID: 28575060)
41. In vitro antileishmanial drug susceptibility of clinical isolates from patients with Indian visceral leishmaniasis--status of newly introduced drugs.
Prajapati VK; Mehrotra S; Gautam S; Rai M; Sundar S
Am J Trop Med Hyg; 2012 Oct; 87(4):655-7. PubMed ID: 22927497
[TBL] [Abstract][Full Text] [Related]
42. Studies on stibanate resistant Leishmania donovani isolates of Indian origin.
Pal S; Mandal A; Duttagupta S
Indian J Exp Biol; 2001 Mar; 39(3):249-54. PubMed ID: 11495284
[TBL] [Abstract][Full Text] [Related]
43. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine.
Yardley V; Croft SL; De Doncker S; Dujardin JC; Koirala S; Rijal S; Miranda C; Llanos-Cuentas A; Chappuis F
Am J Trop Med Hyg; 2005 Aug; 73(2):272-5. PubMed ID: 16103588
[TBL] [Abstract][Full Text] [Related]
44. Genetic markers for antimony resistant clinical isolates differentiation from Indian Kala-azar.
Khanra S; Sarraf NR; Das S; Das AK; Roy S; Manna M
Acta Trop; 2016 Dec; 164():177-184. PubMed ID: 27629023
[TBL] [Abstract][Full Text] [Related]
45. Overexpression of histone H2A modulates drug susceptibility in Leishmania parasites.
Singh R; Kumar D; Duncan RC; Nakhasi HL; Salotra P
Int J Antimicrob Agents; 2010 Jul; 36(1):50-7. PubMed ID: 20427152
[TBL] [Abstract][Full Text] [Related]
46. Evidence of a drug-specific impact of experimentally selected paromomycin and miltefosine resistance on parasite fitness in Leishmania infantum.
Hendrickx S; Beyers J; Mondelaers A; Eberhardt E; Lachaud L; Delputte P; Cos P; Maes L
J Antimicrob Chemother; 2016 Jul; 71(7):1914-21. PubMed ID: 27084919
[TBL] [Abstract][Full Text] [Related]
47. Development of a modified MTT assay for screening antimonial resistant field isolates of Indian visceral leishmaniasis.
Dutta A; Bandyopadhyay S; Mandal C; Chatterjee M
Parasitol Int; 2005 Jun; 54(2):119-22. PubMed ID: 15866473
[TBL] [Abstract][Full Text] [Related]
48. Leishmania donovani chaperonin TCP1γ subunit protects miltefosine induced oxidative damage.
Yadav S; Ali V; Singh Y; Kanojia S; Goyal N
Int J Biol Macromol; 2020 Dec; 165(Pt B):2607-2620. PubMed ID: 33736277
[TBL] [Abstract][Full Text] [Related]
49. The overexpression of genes of thiol metabolism contribute to drug resistance in clinical isolates of visceral leishmaniasis (kala azar) in India.
Singh N; Chatterjee M; Sundar S
Parasit Vectors; 2014 Dec; 7():596. PubMed ID: 25515494
[TBL] [Abstract][Full Text] [Related]
50. Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions.
Rakotomanga M; Saint-Pierre-Chazalet M; Loiseau PM
Antimicrob Agents Chemother; 2005 Jul; 49(7):2677-86. PubMed ID: 15980336
[TBL] [Abstract][Full Text] [Related]
51. Comparative transcript expression analysis of miltefosine-sensitive and miltefosine-resistant Leishmania donovani.
Kulshrestha A; Sharma V; Singh R; Salotra P
Parasitol Res; 2014 Mar; 113(3):1171-84. PubMed ID: 24449447
[TBL] [Abstract][Full Text] [Related]
52. Severe post-kala-azar dermal leishmaniasis successfully treated with miltefosine in an Ethiopian HIV patient.
Abongomera C; Battaglioli T; Adera C; Ritmeijer K
Int J Infect Dis; 2019 Apr; 81():221-224. PubMed ID: 30790722
[TBL] [Abstract][Full Text] [Related]
53. Miltefosine-unresponsive Leishmania donovani has a greater ability than miltefosine-responsive L. donovani to resist reactive oxygen species.
Das M; Saudagar P; Sundar S; Dubey VK
FEBS J; 2013 Oct; 280(19):4807-15. PubMed ID: 23890327
[TBL] [Abstract][Full Text] [Related]
54. Fitness and Phenotypic Characterization of Miltefosine-Resistant Leishmania major.
Turner KG; Vacchina P; Robles-Murguia M; Wadsworth M; McDowell MA; Morales MA
PLoS Negl Trop Dis; 2015; 9(7):e0003948. PubMed ID: 26230675
[TBL] [Abstract][Full Text] [Related]
55. Possible mechanism of miltefosine-mediated death of Leishmania donovani.
Verma NK; Dey CS
Antimicrob Agents Chemother; 2004 Aug; 48(8):3010-5. PubMed ID: 15273114
[TBL] [Abstract][Full Text] [Related]
56. The preclinical discovery and development of oral miltefosine for the treatment of visceral leishmaniasis: a case history.
Reimão JQ; Pita Pedro DP; Coelho AC
Expert Opin Drug Discov; 2020 Jun; 15(6):647-658. PubMed ID: 32202449
[TBL] [Abstract][Full Text] [Related]
57. Genomic and Metabolomic Polymorphism among Experimentally Selected Paromomycin-Resistant Leishmania donovani Strains.
Shaw CD; Imamura H; Downing T; Blackburn G; Westrop GD; Cotton JA; Berriman M; Sanders M; Rijal S; Coombs GH; Dujardin JC; Carter KC
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31658971
[TBL] [Abstract][Full Text] [Related]
58. Genomic Appraisal of the Multifactorial Basis for In Vitro Acquisition of Miltefosine Resistance in Leishmania donovani.
Vacchina P; Norris-Mullins B; Abengózar MA; Viamontes CG; Sarro J; Stephens MT; Pfrender ME; Rivas L; Morales MA
Antimicrob Agents Chemother; 2016 Jul; 60(7):4089-100. PubMed ID: 27114280
[TBL] [Abstract][Full Text] [Related]
59. Antileishmanial and immunomodulatory activities of lupeol, a triterpene compound isolated from Sterculia villosa.
Das A; Jawed JJ; Das MC; Sandhu P; De UC; Dinda B; Akhter Y; Bhattacharjee S
Int J Antimicrob Agents; 2017 Oct; 50(4):512-522. PubMed ID: 28669838
[TBL] [Abstract][Full Text] [Related]
60. A Replicative In Vitro Assay for Drug Discovery against Leishmania donovani.
Tegazzini D; Díaz R; Aguilar F; Peña I; Presa JL; Yardley V; Martin JJ; Coteron JM; Croft SL; Cantizani J
Antimicrob Agents Chemother; 2016 Jun; 60(6):3524-32. PubMed ID: 27021313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
